4,4-dimethyl-morpholinium; hydroxide | 69013-77-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 恶嗪烷类
• 英文名称: 4,4-dimethyl-morpholinium; hydroxide
• 英文别名: 4,4-Dimethyl-morpholinium; Hydroxid；N,N-dimethylmorpholinium hydroxide；4,4-dimethylmorpholin-4-ium;hydroxide
• CAS: 69013-77-0
• 化学式: C₆H₁₄NO*HO
• 分子量: 133.191
• InChiKey: MJUOQIISQATEEV-UHFFFAOYSA-M

计算性质

• 辛醇/水分配系数(LogP)：
  -0.08
• 重原子数：
  9
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  10.2
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  4,4-dimethyl-morpholinium; hydroxide 生成 B-二甲胺基乙基 乙烯基 醚
  参考文献：
  名称：

  Booth,H. et al., Journal of the Chemical Society. Perkin transactions II, 1978, p. 899 - 907

  摘要：

  DOI：
• 作为产物：
  描述：

  N-甲基吗啉 、 碘甲烷 在 1,2-二氯乙烷 、 petroleum ether 作用下， 以 1,2-二氯乙烷 为溶剂， 以to afford 21.3 g of product的产率得到4,4-dimethyl-morpholinium; hydroxide
  参考文献：
  名称：

  Arylsulfinate salts in photoinitiator systems for polymerization reactions

  摘要：

  提供了包括电子给体和敏化化合物的组合物。更具体地，电子给体是芳基磺酸盐。还提供了聚合方法，可用于从光聚物化可聚合组合物中制备聚合材料，该组合物包括乙烯基不饱和单体和光引发剂系统。光引发剂系统包括电子给体和敏化化合物。

  公开号：

  US07732633B2

文献信息

• [DE] VERFAHREN ZUR HERSTELLUNG VON QUARTÄREN AMMONIUM-VERBINDUNGEN<br/>[EN] METHOD FOR PRODUCING QUATERNARY AMMONIUM COMPOUNDS<br/>[FR] PROCÉDÉ DE PRODUCTION DE COMPOSÉS D'AMMONIUM QUATERNAIRES
  申请人：BASF AG

  公开号：WO2005115969A1

  公开（公告）日：2005-12-08

  Die vorliegende Erfindung betrifft ein Verfahren zur Herstellung von quartären Ammo­nium-Verbindungen, bei dem man Verbindungen, die ein sp3-hybridisiertes Stickstoff­atom enthalten, mit einem Dialkylsulfat oder Trialkylphosphat umsetzt und die so erhal­tene Ammonium-Verbindung einem Anionenaustausch unterzieht.

  本发明涉及一种制备季铵化合物的方法，其中将含有sp3杂化氮原子的化合物与二烷基硫酸或三烷基亚磷酸盐反应，然后将得到的铵盐进行离子交换。
• Structural (XRD) and thermal (DSC, TGA) and BET analysis of materials derived from non-metal cation pentaborate salts
  作者：Michael A. Beckett、Peter N. Horton、Michael B. Hursthouse、David A. Knox、James L. Timmis

  DOI：10.1039/b927072h

  日期：——

  The synthesis, structural characterization (XRD), and thermal properties of nine non-metal cation (NMC) pentaborate anion salts, [NMC][B5O6(OH)4] (1a–1i) is described (NMC = [NH3CMe2(CH2OH)]+ (a), [O(CH2CH2)2NH2]+ (b), [NH3CMe(CH2OH)2]+ (c), [2-(2-CH2CH2OH)PyH]+ (d), [(CH2)4NH(CH2CH2OH)]+ (e), [(CH2)5NH(CH2CH2OH)]+ (f), [2-MeImid]+ (g), [Me3NCMe2(CH2OH)]+ (h), [O(CH2CH2)2NMe2]+ (i). Single-crystal X-ray diffraction studies on all compounds show that they contain isolated pentaborate anions, H-bonded together in a supramolecular array, with the cations occupying the cavities within the network. Compound 1c was obtained as a partial hydrate (0.16H2O). TGA and DSC analysis (in air, 25–1000 °C) indicate that compounds 1a–1i thermally decompose via a 2 stage process to B2O3. The first stage (<250 °C) is dehydration to condensed polymeric pentaborates approximate composition: [NMC][B5O8] (2a–2i)}. Five condensed pentaborates (2a–c, 2e, 2g) were synthesised and characterized by powder XRD and BET analysis. These condensed pentaborates were amorphous. The isolated pentaborates intumesced at ∼600 °C (occupying ∼10 times their original volume), and then contracted back to black glassy B2O3 solids at 1000 °C. The intumescent materials (3a), (3b), (3e), (3g), and a final B2O3 sample (4b) were synthesised and isolated and their porosities determined. BET surface area analysis on the isolated pentaborates (1a–c, 1e, 1g), the condensed pentaborates (2a–c, 2e, 2g), intumesced materials (3a, 3b, 3e, 3g), and B2O3 (4b) showed that they were all ‘non-porous’ (<1.59 m2 g−1).

  九种非金属阳离子(NMC)的五硼酸盐阴离子盐[NMC][B5O6(OH)4](1a–1i)的合成、结构表征(XRD)和热性质(NMC = [NH3CMe2(CH2OH)]+(a), [O(CH2CH2)2NH2]+(b), [NH3CMe(CH2OH)2]+(c), [2-(2-CH2CH2OH)PyH]+(d), [(CH2)4NH(CH2CH2OH)]+(e), [(CH2)5NH(CH2CH2OH)]+(f), [2-MeImid]+(g), [Me3NCMe2(CH2OH)]+(h), [O(CH2CH2)2NMe2]+(i)。所有化合物的单晶X射线衍射研究表明，它们含有孤立的五硼酸盐阴离子，通过氢键结合在一起形成超分子排列，阳离子位于网络中的空腔内。化合物1c以部分水合物(0.16H2O)形式获得。TGA和DSC分析(在空气中，25–1000°C)表明，化合物1a–1i通过两阶段过程热分解为B2O3。第一阶段(<250°C)是脱水形成凝聚聚合五硼酸盐近似组成：[NMC][B5O8](2a–2i)}。合成了五种凝聚五硼酸盐(2a–c, 2e, 2g)并通过粉末XRD和BET分析进行了表征。这些凝聚五硼酸盐是无定形的。孤立的五硼酸盐在约600°C时膨胀(占据约原始体积的10倍)，然后在1000°C时收缩回黑色玻璃状B2O3固体。合成了膨胀材料(3a), (3b), (3e), (3g)和最终的B2O3样品(4b)并进行了分离，并测定了它们的孔隙度。对孤立的五硼酸盐(1a–c, 1e, 1g)、凝聚五硼酸盐(2a–c, 2e, 2g)、膨胀材料(3a, 3b, 3e, 3g)和B2O3(4b)的BET比表面积分析显示，它们都是“非多孔”的(<1.59 m2 g−1)。
• Sulfonyl aryl or heteroaryl hydroxamic acid compounds
  申请人：G. D. Searle & Co.,

  公开号：US20030191317A1

  公开（公告）日：2003-10-09

  A sulfonyl aromatic or heteroaromatic ring hydroxamic acid compound that inter alia inhibits matrix metalloprotease activity is disclosed as are a treatment process that comprises administering a contemplated sulfonyl aromatic or heteroaromatic ring hydroxamic acid compound in a MMP enzyme-inhibiting effective amount to a host having a condition associated with pathological matrix metalloprotease activity.

  本发明涉及一种磺酰基芳香或杂芳环羟羧酸化合物，该化合物在抑制基质金属蛋白酶活性方面起作用，还涉及一种治疗方法，包括向与病理性基质金属蛋白酶活性相关病情的宿主投入考虑的磺酰基芳香或杂芳环羟羧酸化合物，其有效量抑制MMP酶活性。
• Use of sulfonyl aryl or heteroaryl hydroxamic acids and derivatives thereof as aggrecanase inhibitors
  申请人：——

  公开号：US20030171404A1

  公开（公告）日：2003-09-11

  This invention is directed to a process for inhibiting aggrecanase activity. The process comprises administering a therapeutically effective amount of a sulfonyl aromatic or heteroaromatic hydroxamic acid, a derivative thereof, or a pharmaceutically acceptable salt of the hydroxamic acid or derivative to a host animal. The compound generally corresponds in structure to the following formula: 1 wherein W and the R groups are described in more detail in Applicants' specification.

  这项发明涉及一种抑制聚集素酶活性的过程。该过程包括向宿主动物施用一定治疗有效量的磺酰芳香或杂芳羟肟酸、其衍生物或羟肟酸或其衍生物的药用盐。该化合物通常与以下结构对应：1其中W和R基的详细描述在申请人的说明书中。
• Sulfonyl aryl hydroxamates and their use as matrix metalloprotease inhibitors
  申请人：——

  公开号：US20030073845A1

  公开（公告）日：2003-04-17

  This invention is directed to sulfonyl aromatic hydroxamic acid compounds and salts thereof that, inter alia, inhibit matrix metalloprotease (MMP) activity and/or aggrecanase activity. In some particularly preferred embodiments, the compound corresponds in structure to one of the following formulas: 1 wherein W 2 , the R groups, and —A—R—E—Y are described in more detail in Applicants' specification. This invention also is directed to a process that comprises administering such a compound or pharmaceutically acceptable salt thereof to a host animal having a condition associated with MMP activity.

  本发明涉及磺酰基芳基羟肟酸化合物及其盐，这些化合物在抑制基质金属蛋白酶（MMP）活性和/或聚集素酶活性方面具有作用。在一些特别优选的实施方式中，该化合物的结构符合以下公式之一：其中W2、R基团和—A—R—E—Y在申请人的说明书中有更详细的描述。本发明还涉及一种过程，该过程包括向患有与MMP活性相关的病况的宿主动物施用这种化合物或其药用可接受盐。